Lasers for Facial Pigmentation and Lentigines
181141811418114
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Omar Ibrahimi, a laser and cosmetic dermatologist, and Mohs surgeon in private practice in Stamford, Conn. Dr. Ibrahimi has about 40 different devices in his practice. Find out his favorites for treating lentigines, and how a patient’s assessment determines his choice of device. Watch …
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Omar Ibrahimi, a laser and cosmetic dermatologist, and Mohs surgeon in private practice in Stamford, Conn. Dr. Ibrahimi has about 40 different devices in his practice. Find out his favorites for treating lentigines, and how a patient’s assessment determines his choice of device. Watch … Continue reading "Lasers for Facial Pigmentation and Lentigines"
ABC News and other media outlets recently covered the story of the World's Smallest Skin Cancer – diagnosed by a team at Oregon Health & Science University and noted by Guinness World Records. How is technology changing melanoma detection? What’s the future?
For expert advice, I reached out to Mohs surgeon Anthony Rossi, MD, assistant attending dermatologist at Memorial Sloan Kettering … 
This article provides practical pearls for performing full body skin exams as shared by a panel of dermatology nurse practitioners (NPs) and physician assistants (PAs) during the 2022 DERM NP/PA CME conference.
Let’s Start with the Basics
What happens before we enter the room?
Before entering the room, it’s always best to:
Review the patient’s chart for pertinent medical hist … 
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. Mark Gimbel, surgical oncologist with Banner MD Anderson Cancer Center, on how molecular tools are revolutionizing how melanoma is diagnosed, treated and prognosticated. Watch Dr. Gimbel explain the current tests on the market and … 
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … 